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Epidemiologic studies have shown that the concentration of high-density lipoprotein
cholesterol (HDL-C) is a strong, independent, inverse predictor of coronary heart disease
risk. This identifies HDL-C as a potential therapeutic target. Compared with low-density
lipoprotein cholesterol (LDL-C)-lowering agents, however, currently available HDL-raising
drugs are relatively ineffective. Consequently, recent years have seen considerable efforts
expended on identifying new drugs that can raise HDL-C. Cholesteryl ester transfer protein
(CETP) plays an important role in cholesterol metabolism, being responsible for the transfer
of cholesteryl esters from HDL to very low-density lipoproteins and LDLs. The observation
that Japanese populations with CETP deficiency exhibited high levels of HDL-C has led to
the concept that drugs targeting CETP activity may elevate HDL-C levels and potentially
decrease cardiovascular risk. Support of this proposition has been obtained in rabbits where
inhibition of CETP activity is markedly antiatherogenic. Two CETP inhibitors—torcetrapib
and JTT-705—are currently in the preliminary stages of clinical development. Initial studies
with these drugs in humans show that they substantially increase HDL-C levels and modestly
decrease LDL-C levels. Larger, long-term, randomized, clinical end point trials are required
to determine whether the beneficial effects of CETP inhibitors on lipoprotein metabolism can
translate into reductions in cardiovascular events. (J Am Coll Cardiol 2006;47:492–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.042© 2006 by the American College of Cardiology Foundation
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tpidemiologic studies have identified high-density lipopro-
ein cholesterol (HDL-C) as a strong, independent, inverse
redictor of coronary heart disease (CHD) risk (1,2). In the
ramingham Heart study, HDL-C was a more potent risk
actor for CHD than low-density lipoprotein cholesterol
LDL-C), total cholesterol, or plasma triglycerides (1). An
nalysis of four large studies has indicated that each 1 mg/dl
ncrease in HDL-C is associated with a 2% to 3% decrease in
he risk of CHD (3). Despite this, evidence from large-scale,
andomized clinical trials that elevating HDL-C reduces risk is
parse (4). The most compelling results, to date, are from the
eterans Affairs High-Density Lipoprotein Cholesterol Inter-
ention trial (VA-HIT) and the Helsinki Heart study (HHS).
n VA-HIT, CHD patients randomized to the fibrate gemfi-
rozil experienced a 6% increase in HDL-C, a 31% decrease
n plasma triglycerides, and no change in LDL-C. Major
oronary events were reduced by 22% compared with
lacebo. The change in HDL-C was significantly associated
ith reductions in coronary events, whereas the change in
riglycerides was not (5). This was also apparent in a
rimary prevention setting in the HHS in which an 8%
ncrease in HDL-C translated into a 24% reduction in
vents, independent of changes in LDL-C and triglycerides
6). Niacin, another HDL-raising agent, has been shown in
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ccepted September 8, 2005.ne long-term trial to achieve a significant reduction in
ajor coronary events, and, in a 15-year follow-up 9 years
fter the trial completed, there was a significant reduction in
otal mortality in the group initially assigned to niacin (7).
tatins also have HDL-raising properties in addition to
heir ability to lower LDL-C, with the statin-induced
ncrease in HDL-C in the Scandinavian Simvastatin Sur-
ival Study (4S) trial contributing significantly to event
eduction (8).
These results have stimulated the search for new more
ffective HDL-raising therapies (9). Here, we review a novel
pproach to increasing HDL-C—inhibition of the cho-
esteryl ester transfer protein (CETP), a plasma protein that
egulates the distribution of cholesterol between HDLs and
DLs (10).
HOLESTEROL METABOLISM
therosclerosis develops and the risk for cardiovascular
isease (CVD) events increases when modified LDL parti-
les are taken up by macrophages in the artery wall to form
oam cells in a process that leads ultimately to the develop-
ent of plaque. In contrast to LDLs, HDLs are antiathero-
enic, partly because of their role in reverse cholesterol
ransport but also due to a spectrum of documented antioxi-
ative, anti-inflammatory, antithrombotic, and antiapoptotic
roperties (11–13). The primary pathways involved in cho-
esterol metabolism and the role that CETP plays in
ransferring triglycerides and cholesteryl esters (CEs) be-
ween lipoproteins are illustrated in Figure 1.
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February 7, 2006:492–9 CETP Inhibition to Prevent CVDDLs. Low-density lipoproteins contain a core of mainly
Es and a small amount of triglycerides surrounded by
urface of phospholipids, free cholesterol, and apolipopro-
ein (apo) B (14). Cholesterol is secreted from the liver into
lasma in very low-density lipoproteins (VLDLs), which in
urn are converted to LDLs. Low-density lipoproteins deliver
holesterol to tissues after binding to the LDL receptor.
DLs. The major protein of HDLs is apo A1, which is
ynthesized in the liver and secreted into plasma in a
Abbreviations and Acronyms
ABCA1  ATP-binding cassette A1
apo  apolipoprotein
CE  cholesteryl ester
CETP  cholesteryl ester transfer protein
CHD  coronary heart disease
CVD  cardiovascular disease
FH  familial hypercholesterolemia
HDL  high-density lipoprotein
HDL-C  high-density lipoprotein cholesterol
HHS  Helsinki Heart study
LDL  low-density lipoprotein
LDL-C  low-density lipoprotein cholesterol
SR-B1  scavenger receptor-B1
VA-HIT  Veterans Affairs High-Density Lipoprotein
Cholesterol Intervention trial
VLDL  very low-density lipoprotein
igure 1. Role of cholesteryl ester transfer protein (CETP) in plasma lip
shown by the red arrows) of cholesteryl esters (CE) and triglycerides (T
VLDLs), and low-density lipoproteins (LDLs). Most of the CEs in plasma
LCAT), while the majority of the TG enters plasma as a component of TG
s chylomicrons. Very low-density lipoproteins are subsequently conve
ipase (LPL) and hepatic lipase (HL). The overall effect of the CETP-m
rom the antiatherogenic HDLs to the potentially proatherogenic VLDLs
eripheral tissues) that express the LDL receptor. Modified (oxidized) LD
hat converts the macrophage into a foam cell. Cholesterol, both in its fre
iver by HDLs via the scavenger receptor-B1 (SR-B1) (pathway 1) and by LDLs
hrough which peripheral cells may efflux cholesterol to HDL particles.ipid-poor form. Lipid-poor apo A1 rapidly acquires free
holesterol from tissues via the adenosine triphosphate
ATP)-binding cassette A1 (ABCA1) transporter to form
iscoidal HDL particles. Discoidal HDLs interact with
ecithin:cholesterol acyltransferase, which converts a pro-
ortion of their free cholesterol into CEs that migrate into
hydrophobic core in a process that converts the disc into a
ature, spherical HDL particle (Fig. 2). The fact that discoi-
al HDL particles are normally present at only very low
oncentration in plasma reflects the rapidity with which they
re converted into spheres. The cholesterol in mature HDL
articles interacts with the hepatic scavenger receptor class
type 1 (SR-B1) to deliver cholesterol (mainly as free
holesterol) to the liver (Fig. 1) (15). The process of
ransferring cholesterol from peripheral cells to the liver for
emoval from the body by biliary secretion is called reverse
holesterol transport. The role of HDLs in facilitating reverse
holesterol transport is one of the mechanisms by which
DLs protect against atherogenesis.
It has recently become clear that ABCA1 is not the only
eans by which peripheral cells can efflux cholesterol to
DLs. Other mechanisms include interaction of HDLs
ith SR-B1 (16) and passive diffusion (17). Another trans-
orter, the ATP-binding cassette G1, is expressed in mac-
ophages where it promotes the efflux of cholesterol from
he cell to mature, spherical HDLs (Fig. 2) (18,19).
nsport. Cholesteryl ester transfer protein promotes bidirectional transfers
etween high-density lipoproteins (HDLs), very low-density lipoproteins
nate in HDLs in a reaction catalyzed by lecithin:cholesterol acyltransferase
lipoproteins secreted either from the liver as VLDLs or from the intestine
nto LDLs after hydrolysis of a proportion of their TG by lipoprotein
ed CE exchanges between these lipoproteins is a net mass transfer of CE
DLs. The cholesterol in LDLs is taken up by all cells (both in liver and
e also taken up by macrophages in a scavenger receptor-mediated process
nesterified form (FC) and in its esterified form as CE, is returned to theid tra
G) b
origi
-rich
rted i
ediat
and L
Ls ar
e or uvia the LDL receptor (LDL-R) (pathway 2). See Figure 2 for mechanisms
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CETP Inhibition to Prevent CVD February 7, 2006:492–9ole of CETP. Cholesteryl ester transfer protein is secreted
y the liver and is a key player in the metabolic interaction
etween HDLs and the VLDL-LDL fraction. It is a hydro-
hobic plasma glycoprotein that circulates bound mainly to
DLs (20). The primary function of CETP is to redistribute
Es and triglycerides between lipoproteins (Fig. 1) (12).
ecause most triglycerides in plasma originate in VLDLs and
ost CEs are formed in HDL particles in the reaction
atalyzed by lecithin:cholesterol acyltransferase, activity of
ETP results in a net mass transfer of triglycerides from
LDLs to LDLs and HDLs and a net mass transfer of CEs
rom HDLs to VLDLs and LDLs (10). The exchanges
etween HDLs and VLDLs provide one explanation for the
ow level of HDL-C in people with hypertriglyceridemia.
nce CEs are transferred from HDLs to VLDLs and
DLs, they are available for uptake by the liver after binding
f LDLs to the LDL receptor (Fig. 1) (21).
OES CETP PROMOTE ATHEROGENESIS?
HEORETICAL CONSIDERATIONS
hether CETP activity is atherogenic remains a matter of
ebate. Although various dyslipidemias have been linked
ith increased CETP concentrations (22–24), it is possible
igure 2. Efflux of cholesterol from peripheral cells. High-density lipopro
everal mechanisms. The ATP-binding cassette transporter A1 (ABCA1)
iscoidal, nascent HDL. Esterification of the FC in nascent HDL by
articles. The lipidation of lipid-poor apo A1 and the conversion of disco
ipid-poor apo A1 and discoidal HDL in normal plasma. Free cholest
eceptor-mediated pathway, including the scavenger receptor B-1 (SR-B1)
hospholipid.hat elevated CETP is the result of dyslipidemia rather than cts cause (25). Indeed, by promoting the transfer of CEs
rom HDLs to VLDLs and LDLs, activity of CETP may
ccount for a considerable proportion of the peripheral cell
holesterol that is returned to the liver in humans (15,21).
n this respect, CETP may be viewed as having antiathero-
enic activity. On the other hand, by transferring CEs from
DLs to VLDLs and LDLs, CETP decreases the concen-
ration of antiatherogenic HDLs while increasing the con-
entration of LDL-C (21).
The CETP-mediated exchange of CEs and triglycerides
lso alters the size and structure and potential atherogenicity
f lipoprotein particles. As triglycerides in VLDLs are
xchanged for CEs in HDLs and LDLs, the HDL and
DL particles become triglyceride-enriched. Such particles
re substrates for triglyceride lipases, which hydrolyze the
riglycerides and in the process generate small, dense LDLs
nd small, dense HDLs (Fig. 3) (26). Small, dense LDLs
re more atherogenic than larger LDLs (27), because they
ave greater affinity for artery wall proteoglycans (28) and
re more readily modified by oxidation before macrophage
ptake (29,30). The formation of small, dense HDLs is
ccompanied by the dissociation of lipid-poor apo A1 (Fig. 3)
31). This lipid-poor apo A1 may then act as an acceptor of
HDL) particles may accept free cholesterol (FC) from peripheral cells via
es FC to lipid-poor apolipoprotein (apo) A1 resulting in the formation of
n:cholesterol acyltransferase (LCAT) generates spherical, mature HDL
DL to spherical particles are rapid as evidenced by the very low levels of
ay be effluxed to mature HDL particles by passive diffusion or by a
e newly identified ATP-binding cassette transporter G1 (ABCG1). PL tein (
efflux
lecithi
idal H
erol mell cholesterol in the process mediated by ABCA1 (31,32).
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February 7, 2006:492–9 CETP Inhibition to Prevent CVDlternatively, however, it may be removed by the kidney
nd lost irreversibly from plasma (33). Not surprisingly,
atients with CETP deficiency have an increased propor-
ion of large CE-rich HDL particles (34,35). Conversely, an
ncrease in the CETP-mediated exchanges of triglycerides
nd CEs between HDLs and VLDLs in individuals with
levated triglyceride levels results not only in a reduced
oncentration of HDL-C but also a reduction in the HDL
article size (36,37). The impact of CETP on LDL particle
ize has also been observed in patients with familial hyper-
holesterolemia (FH). In a study by Hogue et al. (38),
atients with heterozygous FH had a higher CETP mass
han non-FH controls, and an inverse relationship was
bserved between LDL peak particle diameter and CETP
ass.
To summarize, CETP plays an important role in several
ey pathways of cholesterol metabolism and theoretically
ay be associated with both pro- and antiatherogenic
ctivity.
ETP AND ATHEROSCLEROSIS—
VIDENCE FROM ANIMAL AND HUMAN STUDIES
ouse studies. Mice are naturally deficient in activity of
ETP and relatively resistant to the development of ath-
rosclerosis. Introduction of the CETP gene into mice
educes the level of HDL-C and increases susceptibility to
igure 3. Effect of cholesteryl ester transfer protein (CETP) on lipopro
riglycerides (TG) from TG-rich lipoproteins to high-density lipoprotein
CE). Through the action of TG lipases, HDL particles decrease in size a
1 may be reused in the first step of reverse cholesterol transport as an ac
riglyceride lipases similarly reduce the size of LDL particles. The resultan
rterial macrophages. VLDL  very low-density lipoprotein.iet-induced atherosclerosis (39,40). A study in APOE*3- oeiden mice expressing CETP and fed a Western-style diet
howed a seven-fold increase in the atherosclerotic lesion
rea after 19 weeks compared with APOE*3-Leiden mice
ot expressing CETP (41). However, studies in hypertri-
lyceridemic mice have shown that expression of CETP is
ntiatherogenic (42,43). Thus, studies in mice have pro-
ided inconsistent findings.
abbit studies. In contrast to mice, rabbits have a high
evel of CETP activity in plasma and are an ideal model in
hich to investigate the effects of CETP inhibition. Injec-
ion of anti-sense oligodexynucleotides against CETP into
holesterol-fed rabbits has been shown to reduce CETP
RNA and mass, to increase in HDL-C levels, and to
educe aortic plaque formation (44). In another study of
holesterol-fed rabbits, an autoimmune response against
ETP was induced by a vaccine. This led to a reduction in
ETP activity, an increase in HDL-C, and again a reduc-
ion in aortic plaque formation (45). There have also been
tudies of the effects of small molecule CETP inhibitors in
abbits. In cholesterol-fed rabbits, the CETP inhibitor
TT-705 increased plasma HDL-C, decreased non-
DL-C, and decreased aortic arch lesions by 70% (46).
owever, in a subsequent study of JTT-705, also conducted
n rabbits, the difference in the deposition of aortic choles-
erol was not significantly different from the control group,
espite a similar elevation in HDL-C compared with the
particle size. Cholesteryl ester transfer protein mediates the transfer of
L) and low-density lipoprotein (LDL) in exchange for cholesteryl esters
olipoprotein (Apo) A1 dissociates from HDL. Although dissociated Apo
r of cholesterol effluxed from cells, it may also be lost by renal clearance.
all, dense LDL is more susceptible to oxidation and subsequent uptake bytein
(HD
nd ap
ceptoriginal study (47). The CETP inhibitor torcetrapib has
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CETP Inhibition to Prevent CVD February 7, 2006:492–9lso been shown in cholesterol-fed rabbits to increase the
evel of HDL-C and to reduce aortic atherosclerosis (48).
uman studies. The notion that CETP may be a potential
arget for reducing CVD originated from reports of a
apanese population of apparently healthy individuals that
acked a functional copy of the CETP gene (34,35).
ompared with unaffected individuals, those who were
ETP-deficient and who had no measurable CETP activity
n plasma exhibited substantial increases in HDL-C (209%)
nd large decreases in LDL-C (44%). In individuals with
eterozygous deficiency who possessed half the normal
ETP activity, changes in HDL-C and LDL-C were less
ramatic (25% and 5%, respectively).
While CETP gene mutations are common in Japanese
opulations (49) and have clearly helped to establish the link
etween reduced CETP function and elevated HDL-C
evels, the effect of decreased CETP activity on the devel-
pment of atherosclerosis is less clear. For example, in a
tudy of 201 patients with markedly elevated HDL-C levels
100 mg/dl), a subgroup of 12 patients (6%) was identified
ith atherosclerotic CVD. Of these, 10 were observed to be
eterozygotes for CETP deficiency (50). Data from the
onolulu Heart Program regarding CETP concentrations
nd CHD risk are also inconsistent. The study included
merican men of Japanese ancestry, many of whom were
eterozygous for a mutation in the CETP gene and had
educed CETP levels. The data that were originally pub-
ished suggested an apparent 50% increase in CHD among
articipants with CETP deficiency and HDL-C levels of 41
o 60 mg/dl (51). However, more recent, seven-year pro-
pective data have now shown the opposite, with the
ETP-deficient individuals experiencing fewer CHD
vents than those without the mutation, although the
ifference did not achieve statistical significance (52).
In an attempt to elucidate the relationship between
ETP activity and CHD risk, numerous studies have
nvestigated polymorphisms of the CETP gene in which
nly one or two amino acids are changed (53).
One of the more common CETP polymorphisms is
aq1B in intron 1. In one study, this polymorphism
ccounted for 5.8% of the variance in HDL-C levels (54),
nd, in the Framingham Offspring study, individuals ho-
ozygous for the B1 allele had higher levels of CETP and
ower levels of HDL-C compared with either B1B2 or
2B2 subjects. In men, the presence of the B2 allele reduced
he risk of CHD, although there was no significant associ-
tion in women (55). A recent meta-analysis of data from
even population-based studies and three randomized, con-
rolled trials has since demonstrated that Taq1B is firmly
ssociated both with HDL-C plasma levels and with risk of
HD (56).
The beneficial effects of another CETP gene polymor-
hism have been reported in a study of exceptionally
ong-lived individuals from a genetically homogeneous popu-
ation of Ashkenazi Jews (57). Healthy individuals of advanced
ge (95 to 107 years) in this population had a unique lipopro- aein profile consisting of large HDL and LDL particles. Their
ffspring also had lipoprotein particles of larger size compared
ith those of an age-matched control group of Ashkenazi
ews and with those of individuals from the Framingham
ffspring study. In both the individuals with exceptional
ongevity and their offspring, the incidence of homozygosity
or a CETP polymorphism was significantly higher than
n either of the control groups. The CETP polymorphism
as associated with reduced CETP levels and CETP
ctivity, and with larger lipoprotein particle size, leading
nvestigators to conclude that it was an important factor
n the survival advantage apparent among the long-lived
ndividuals.
Although sparse, there is evidence emerging from clinical
rials that elevated CETP levels are associated with in-
reased risk of atherosclerosis. An analysis of baseline
ETP levels in 674 men with CHD in the Regression
rowth Evaluation Statin Study (REGRESS) revealed that
hose with baseline CETP concentrations in the highest
uartile had significantly greater progression of coronary
therosclerosis after two years than those with baseline
ETP concentrations in the lowest quartile (58). Likewise,
n analysis of data from 281 patients with FH who
articipated in the Atorvastatin Simvastatin Atherosclerosis
rogression (ASAP) trial showed a positive association
etween baseline CETP concentration and progression of
therosclerosis as measured by change in carotid intima
hickness (22).
Perhaps the most convincing data supporting a link
etween baseline CETP concentration and CHD risk come
rom a recent nested case-control study conducted among
articipants of the European Prospective Investigation into
ancer and Nutrition (EPIC)-Norfolk Population study
59). This study identified 755 apparently healthy individ-
als who went on to develop fatal or nonfatal CHD during
ollow-up and control subjects who remained free of CHD
uring follow-up. The risk of CHD increased with increas-
ng CETP quintiles, although this relationship was confined
o those with elevated triglyceride levels.
ETP INHIBITION AS A THERAPEUTIC
TRATEGY FOR REDUCING CARDIOVASCULAR RISK
n balance, the currently available data suggest that de-
reased CETP activity is antiatherogenic, particularly if
ssociated with an increase in HDL-C levels. Inhibition of
ETP is now being investigated as a potential new strategy
or the management of CVD. A vaccine, CETi-1, and two
mall-molecule compounds, JTT-705 and torcetrapib, are
urrently under investigation in humans.
ETi-1. The vaccine CETi-1 induces auto-antibodies
hat specifically bind and inhibit the activity of endogenous
ETP.
In a phase I human study with CETi-1, one patient at the
ighest dose (250 mg) of a total of 36 patients who received
single injection developed anti-CETP antibodies. In an
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February 7, 2006:492–9 CETP Inhibition to Prevent CVDxtension study of 23 patients, 53% (8 of 15) who received
second injection of the active vaccine developed anti-
ETP antibodies compared with 0% (0 of 8) in the placebo
roup (60). The vaccine was well tolerated, and no signifi-
ant laboratory abnormalities occurred. The effect of the
accine on the concentration of HDL-C in humans has not
et been reported.
TT-705. JTT-705 inhibits CETP activity by forming a
isulfide bond that causes irreversible binding to the protein.
In a phase II, randomized, double-blind, placebo-
ontrolled study of 198 healthy individuals with mild
yslipidemia, JTT-705 was evaluated at doses of 300, 600,
nd 900 mg/day (61). A dose-dependent decrease in CETP
ctivity was measured, reaching a maximum decrease of 37%
rom baseline after four weeks of treatment at the 900
g/day dose. At this dose, HDL-C was increased by 34%.
ecreases in LDL-C levels were minimal.
JTT-705 in combination with pravastatin has been as-
essed in a randomized, double-blind, placebo-controlled
rial conducted in 152 individuals with LDL-C 160
g/dl. Patients were randomized into three study arms:
lacebo and pravastatin 40 mg, JTT-705 300 mg with
ravastatin 40 mg, and JTT-705 600 mg with pravastatin 40
g. After four weeks, JTT-705 600 mg plus pravastatin led
o a 30% decrease from baseline in CETP activity and a 28%
ncrease from baseline in HDL-C (p  0.001 for both
arameters vs. placebo), while LDL-C decreased by 5%
rom baseline. JTT-705 300 mg plus pravastatin was about
alf as effective as the higher dose, decreasing CETP
ctivity by approximately 16% and increasing HDL-C by
pproximately 14% (62).
orcetrapib. Torcetrapib is a potent and selective inhibitor
f CETP. It enhances the association between CETP and
DLs, forming a complex that inhibits the transfer of lipids
etween HDLs and other lipoproteins.
Torcetrapib has been evaluated in two small, placebo-
ontrolled studies (63,64).
In one study, 40 healthy young subjects were randomized
o receive placebo or increasing doses of torcetrapib from 10
o 240 mg daily for 14 days (63). Activity of CETP was
educed by 12% to 80%. The concentration of HDL-C
ncreased by 16% to 91% and that of LDL-C decreased by
1% to 42%. These changes were associated with elevations
n apo A1 and apoE and reductions in apoB. In another
eport of the effects of torcetrapib (64), 19 subjects with
oncentrations of HDL-C less than 40 mg/dl were treated
ith torcetrapib at doses up to 120 mg twice daily. Some
ubjects also received atorvastatin. Treatment with torce-
rapib at a daily dose of 120 mg increased HDL-C by 61%
nd 46% in the presence and absence of concomitant
torvastatin therapy, respectively. At a dose of 120 mg twice
aily, torcetrapib increased HDL-C by 106%. The mean size
f both HDL and LDL particles increased with torcetrapib
herapy (64), an observation consistent with previous reports
f large HDL particles in individuals with a partial or
omplete genetic deficiency of CETP.It has been reported recently that torcetrapib does not
ncrease overall reverse cholesterol transport in humans (as
easured by fecal sterol excretion) (65), although it should
e emphasized that this technique tells us nothing about the
mpact of the drug on the efflux of cholesterol from
acrophages in the artery wall. The true test of whether
ETP inhibition is cardioprotective in humans will have to
wait the results of the ongoing clinical trials, the first of
hich should report some time in 2007.
ONCLUSIONS
hile epidemiologic evidence has demonstrated a clear link
etween low levels of HDL-C and increased CHD risk,
here are limited data on the benefits of elevating HDL-C
hrough pharmacologic intervention. This may be be-
ause existing therapies achieve only moderate increases
n HDL-C.
Cholesteryl ester transfer protein appears to have a
umber of potentially proatherogenic effects, including de-
reasing HDL-C levels, increasing LDL-C levels, and
educing HDL and LDL particle size. Inhibitors of CETP
re in clinical development and have been shown to have a
avorable impact on the lipoprotein profile and may
otentially be a new strategy for reducing CVD. Large-
cale, randomized trials evaluating the impact of these
nhibitors on atherosclerotic progression using vascular
maging and on the incidence of cardiovascular events are
ow required.
eprint requests and correspondence: Dr. Philip J. Barter, The
eart Research Institute, 145 Missenden Road, Camperdown,
ydney 2050, Australia. E-mail: p.barter@hri.org.au.
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